Comera Life Sciences Holdings Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 16

Employees

  • Latest Deal Type
  • PIPE

  • Latest Deal Amount
  • $4.1M

  • Investors
  • 3

Comera Life Sciences Holdings General Information

Description

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Contact Information

Formerly Known As
ReForm Biologics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 12 Gill Street
  • Suite 4650
  • Woburn, MA 01801
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • 12 Gill Street
  • Suite 4650
  • Woburn, MA 01801
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Comera Life Sciences Holdings Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. PIPE 12-Sep-2023 $4.1M Completed Generating Revenue
6. PIPE 04-Jan-2023 Completed Generating Revenue
5. PIPE 31-Aug-2022 Completed Generating Revenue
4. PIPE 20-May-2022 Completed Generating Revenue
3. Reverse Merger 19-May-2022 Completed Generating Revenue
2. Later Stage VC (Series B) 21-Jul-2021 $10M $24.6M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 04-Apr-2018 $14.6M $14.6M Completed Startup
To view Comera Life Sciences Holdings’s complete valuation and funding history, request access »

Comera Life Sciences Holdings Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A-6
Series A-5
Series A-4
Series A-3
Series A-2 1,266,667 $0.001000 $1.5 $1.5 1x $1.5 6.67%
Series A-1 6,000,000 $0.001000 $1 $1 1x $1 31.6%
To view Comera Life Sciences Holdings’s complete cap table history, request access »

Comera Life Sciences Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and
Biotechnology
Woburn, MA
16 As of 2023

San Diego, CA
 

San Jose, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Comera Life Sciences Holdings Competitors (7)

One of Comera Life Sciences Holdings’s 7 competitors is Halozyme Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Halozyme Therapeutics Formerly VC-backed San Diego, CA
Rani Therapeutics Formerly VC-backed San Jose, CA
Lindy Biosciences Venture Capital-Backed Morrisville, NC
Athos Therapeutics Venture Capital-Backed Los Angeles, CA
Alteogen Formerly VC-backed Daejeon, South Korea
You’re viewing 5 of 7 competitors. Get the full list »

Comera Life Sciences Holdings Patents

Comera Life Sciences Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023091370-A1 Excipient compounds for biopolymer formulations Inactive 16-Nov-2021
EP-4210757-A2 Excipient compounds for protein formulations Inactive 11-Sep-2020
EP-4210757-A4 Excipient compounds for protein formulations Inactive 11-Sep-2020
US-20250186600-A1 Excipient compounds for protein formulations Inactive 11-Sep-2020
WO-2022056220-A2 Excipient compounds for protein formulations Inactive 11-Sep-2020 A61K39/39591
To view Comera Life Sciences Holdings’s complete patent history, request access »

Comera Life Sciences Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Comera Life Sciences Holdings Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arena Investors PE/Buyout Minority
KBI BioPharma Corporation Minority
Life Science Venture Capital Corporate Venture Capital Minority
Phoenix Venture Partners Venture Capital Minority
To view Comera Life Sciences Holdings’s complete investors history, request access »

Comera Life Sciences Holdings Acquisitions (1)

Comera Life Sciences Holdings’s most recent deal was a Merger/Acquisition with OTR Acquisition. The deal was made on 19-May-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OTR Acquisition 19-May-2022 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Comera Life Sciences Holdings’s complete acquisitions history, request access »

Comera Life Sciences Holdings ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Comera Life Sciences Holdings’s complete esg history, request access »

Comera Life Sciences Holdings FAQs

  • When was Comera Life Sciences Holdings founded?

    Comera Life Sciences Holdings was founded in 2014.

  • Where is Comera Life Sciences Holdings headquartered?

    Comera Life Sciences Holdings is headquartered in Woburn, MA.

  • What is the size of Comera Life Sciences Holdings?

    Comera Life Sciences Holdings has 16 total employees.

  • What industry is Comera Life Sciences Holdings in?

    Comera Life Sciences Holdings’s primary industry is Biotechnology.

  • Is Comera Life Sciences Holdings a private or public company?

    Comera Life Sciences Holdings is a Private company.

  • What is Comera Life Sciences Holdings’s current revenue?

    The current revenue for Comera Life Sciences Holdings is .

  • How much funding has Comera Life Sciences Holdings raised over time?

    Comera Life Sciences Holdings has raised $48.3M.

  • Who are Comera Life Sciences Holdings’s investors?

    Arena Investors, KBI BioPharma, Life Science Venture Capital, and Phoenix Venture Partners have invested in Comera Life Sciences Holdings.

  • Who are Comera Life Sciences Holdings’s competitors?

    Halozyme Therapeutics, Rani Therapeutics, Lindy Biosciences, Athos Therapeutics, and Alteogen are some of the 7 competitors of Comera Life Sciences Holdings.

  • When was Comera Life Sciences Holdings acquired?

    Comera Life Sciences Holdings was acquired on 12-Sep-2023.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process